Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Insulet target raised to $50 at Wedbush; Solid quarter, healthy outlook (46.17)Wedbush raises their PODD tgt to $50 from $48 after co posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new mgmt continues to fire on all cylinders with better-than-expected revs across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within co's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017; Outperform.</td> </tr></table>"